EuroPharma® Forms Joint Venture with VitaPlant, Highly Respected Swiss Research Institute

Green Bay, WI (August 12, 2005) – EuroPharma, a Green Bay, Wisconsin-based natural products research and development company, has entered into a joint venture with VitaPlant, the exceedingly well-respected Swiss research institute for phytomedicinal products. The announcement was made by Terry Lemerond, EuroPharma’s founder and president.

EuroPharma is currently funding six new research projects with VitaPlant in the development of new plant-based medicines. These new phytomedicinal products will be commercially available worldwide in 12 to 18 months. EuroPharma will seek partnerships with US marketing companies to introduce the products here.

This joint venture is important to the dietary supplement industry in that together, EuroPharma and VitaPlant will help elevate the standards of products, an area that most industry leaders agree is critical. Mr. Lemerond noted, “Science is an important factor in the development of new products and is key to the growth and credibility of our industry.”

“There is a growing tendency towards more scientifically-researched ingredients and products in the herb and dietary supplement industry,” said Mark Blumenthal, Founder and Executive Director of the American Botanical Council, an independent nonprofit organization that focuses on scientific research of herbs, phytomedicines, and plant-based ingredients. “Consumers, healthcare practitioners and the public in general are demanding high quality supplement products that are well documented for their safety and health benefits.”

VitaPlant’s experienced natural product scientists research and develop new applications for the phytomedicinal world. VitaPlant acts as a think tank, opening new horizons and opportunities in the field of naturally-derived therapeutic strategies. Key VitaPlant competencies include experimental pharmacology and toxicology, phytopharmaceutical technology, medicinal plant breeding for variety protection, molecular marker techniques, in vitro and in vivo propagation of elite plants, domestication and controlled cultivation of plants.

Dr. Bernd Bueter and Dr. Karin Berger Bueter founded VitaPlant in 1996. Employing a patented, bioassay guided breeding approach, Dr. Bernd Bueter has developed several new medicinal plant varieties and cultivars. Dr. Matthias H. Kreuter, VitaPlant’s Scientific Director, has 15 years experience researching phytomedicines. Dr. Kreuter is the author of more than 25 patents in the field of plant extraction and applications worldwide.

“VitaPlant represents the cutting edge of science applied to medicinal plant research with the intentional result of developing products to enhance people’s health. We are dedicated to introducing VitaPlant to those companies that are interested in serious research to support the safety and efficacy of their product offerings,” said EuroPharma’s Lemerond.

“We are happy to join forces with EuroPharma as our representative for North America. Terry’s integrity, reputation and professionalism along with his broad network of companies in North America make us confident that EuroPharma is the perfect partner for us,” said Dr. Bernd Bueter.

Located in Basel, Switzerland, in the heart of the pharmaceutical industry of Europe, VitaPlant has a mission to discover new fields of applications for the phytomedicinal world. For more information visit www.vitaplant.ch.

Located in Green Bay, Wisconsin, EuroPharma, Inc., is committed to discovering innovative products that have been extensively researched and demonstrated to be safe, natural and effective which will help people live healthier and more fulfilling lives. EuroPharma’s mission is to bring truly unique and industry-changing products to the U.S. marketplace. EuroPharma is an extension of its founder Terry Lemerond’s historic successes and a proven model of product development. For more information, visit www.EuroPharmaUSA.com.

- END -

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish